Metallothionein (MT) has been extensively investigated as a molecular marker of various types of cancer. In spite of the fact that numerous reviews have been published in this field, no meta-analytical approach has been performed. Therefore, results of to-date immunohistochemistry-based studies were summarized using meta-analysis in this review. Web of science, PubMed, Embase and CENTRAL databases were searched (up to April 30, 2013) and the eligibility of individual studies and heterogeneity among the studies was assessed. Random and fixed effects model meta-analysis was employed depending on the heterogeneity, and publication bias was evaluated using funnel plots and Egger's tests. A total of 77 studies were included with 8,015 tissue samples (4,631 cases and 3,384 controls). A significantly positive association between MT staining and tumors (vs. healthy tissues) was observed in head and neck (odds ratio, OR 9.95; 95% CI 5.82–17.03) and ovarian tumors (OR 7.83; 1.09–56.29), and a negative association was ascertained in liver tumors (OR 0.10; 0.03–0.30). No significant associations were identified in breast, colorectal, prostate, thyroid, stomach, bladder, kidney, gallbladder, and uterine cancers and in melanoma. While no associations were identified between MT and tumor staging, a positive association was identified with the tumor grade (OR 1.58; 1.08–2.30). In particular, strong associations were observed in breast, ovarian, uterine and prostate cancers. Borderline significant association of metastatic status and MT staining were determined (OR 1.59; 1.03–2.46), particularly in esophageal cancer. Additionally, a significant association between the patient prognosis and MT staining was also demonstrated (hazard ratio 2.04; 1.47–2.81). However, a high degree of inconsistence was observed in several tumor types, including colorectal, kidney and prostate cancer. Despite the ambiguity in some tumor types, conclusive results are provided in the tumors of head and neck, ovary and liver and in relation to the tumor grade and patient survival.
References
[1]
Nordberg M, Nordberg GF (2000) Toxicological aspects of metallothionein. Cellular and Molecular Biology 46: 451–463.
[2]
Miles AT, Hawksworth GM, Beattie JH, Rodilla V (2000) Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Critical Reviews in Biochemistry and Molecular Biology 35: 35–70.
[3]
Krizkova S, Ryvolova M, Hrabeta J, Adam V, Stiborova M, et al. (2012) Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metabolism Reviews 44: 287–301.
[4]
Hanada K, Sawamura D, Tamai K, Baba T, Hashimoto I, et al. (1998) Novel function of metallothionein in photoprotection: Metallothionein-null mouse exhibits reduced tolerance against ultraviolet B injury in the skin. Journal of Investigative Dermatology 111: 582–585.
[5]
Reeve VE, Nishimura N, Bosnic M, Michalska AE, Choo KHA (2000) Lack of metallothionein-I and -II exacerbates the immunosuppressive effect of ultraviolet B radiation and cis-urocanic acid in mice. Immunology 100: 399–404.
[6]
Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, et al. (1993) Metallothionein in testicular germ-cell tumors and drug-resistance - clinical correlation. Cancer 72: 3029–3035.
[7]
Fuertes MA, Alonso C, Perez JM (2003) Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chemical Reviews 103: 645–662.
[8]
Sunada F, Itabashi M, Ohkura H, Okumura T (2005) p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World Journal of Gastroenterology 11: 5696–5700.
[9]
Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, et al. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813–1815.
[10]
Kumar SD, Vijaya M, Samy RP, Dheen ST, Ren MQ, et al. (2012) Zinc supplementation prevents cardiomyocyte apoptosis and congenital heart defects in embryos of diabetic mice. Free Radical Biology and Medicine 53: 1595–1606.
[11]
Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, et al. (2012) Mammalian metallothioneins: properties and functions. Metallomics 4: 739–750.
[12]
Tsangaris GT, Tzortzatou-Stathopoulou F (1998) Metallothionein expression prevents apoptosis: A study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. Anticancer Research 18: 2423–2433.
[13]
Eckschlager T, Adam V, Hrabeta J, Figova K, Kizek R (2009) Metallothioneins and Cancer. Current Protein and Peptide Science 10: 360–375.
[14]
Cherian MG, Jayasurya A, Bay BH (2003) Metallothioneins in human tumors and potential roles in carcinogenesis. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 533: 201–209.
[15]
Ebadi M, Leuschen MP, ElRefaey H, Hamada FM, Rojas P (1996) The antioxidant properties of zinc and metallothionein. Neurochemistry International 29: 159–166.
[16]
Kang YJ (2006) Metallothionein redox cycle and function. Experimental Biology and Medicine 231: 1459–1467.
[17]
Sato M, Bremner I (1993) Oxygen free-radicals and metallothionein Free Radical Biology and Medicine. 14: 325–337.
[18]
Iszard MB, Liu J, Klassen CD (1995) Effect of several metallothionein inducers on oxidative stress defense mechanisms in rats. Toxicology 104: 25–33.
[19]
Aschner M, Conklin DR, Yao CP, Allen JW, Tan KH (1998) Induction of astrocyte metallothioneins (MTs) by zinc confers resistance against the acute cytotoxic effects of methylmercury on cell swelling, Na+ uptake, and K+ release. Brain Research 813: 254–261.
[20]
Namdarghanbari M, Wobig W, Krezoski S, Tabatabai N, Petering D (2011) Mammalian metallothionein in toxicology, cancer, and cancer chemotherapy. Journal of Biological Inorganic Chemistry 16: 1087–1101.
[21]
Cai L, Koropatnick J, Cherian MG (1995) Metallothionein protects DNA from copper-induced but not iron-induced cleavage in-vitro. Chemico-Biological Interactions 96: 143–155.
[22]
Shibuya K, Nishimura N, Suzuki JS, Tohyama C, Naganuma A, et al. (2008) Role of metallothionein as a protective factor against radiation carcinogenesis. Journal of Toxicological Sciences 33: 651–655.
[23]
Schwarz MA, Lazo JS, Yalowich JC, Allen WP, Whitmore M, et al. (1995) Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric-oxide. Proceedings of the National Academy of Sciences of the United States of America 92: 4452–4456.
[24]
Kondo Y, Rusnak JM, Hoyt DG, Settineri CE, Pitt BR, et al. (1997) Enhanced apoptosis in metallothionein null cells. Molecular Pharmacology 52: 195–201.
[25]
Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH (2007) Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatology Research 37: 820–827.
[26]
Pedersen MO, Larsen A, Stoltenberg M, Penkowa M (2009) The role of metallothionein in oncogenesis and cancer prognosis. Progress in Histochemistry and Cytochemistry 44: 29–64.
[27]
Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP (2004) Metallothionein expression in human neoplasia. Histopathology 45: 103–118.
[28]
Takahashi S (2012) Molecular functions of metallothionein and its role in hematological malignancies. Journal of Hematology & Oncology 5.
[29]
Gumulec J, Masarik M, Krizkova S, Hlavna M, Babula P, et al. (2012) Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. Neoplasma 59: 191–200.
[30]
Jin RX, Huang JX, Tan PH, Bay BH (2004) Clinicopathological significance of metallothioneins in breast cancer. Pathology & Oncology Research 10: 74–79.
[31]
Bay BH, Jin RX, Jayasurya A (2001) Analysis of metallothionein expression in human cancers. Acta Histochemica et Cytochemica 34: 171–176.
[32]
Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21: 1539–1558.
[33]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
[34]
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods 1: 97–111.
[35]
Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, et al. (2006) Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. British Journal of Cancer 94: 835–841.
[36]
Perez-Gutierrez S, Gonzalez-Campora R, Amerigo-Navarro J, Beato-Moreno A, Sanchez-Leon M, et al. (2007) Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. Pathology & Oncology Research 13: 203–208.
[37]
Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, et al. (2000) Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environmental Health Perspectives 108: 413–418.
[38]
Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, et al. (2012) Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Human Pathology 43: 197–208.
[39]
Ioachim EE, Goussia AC, Agnantis NJ, Machera M, Tsianos EV, et al. (1999) Prognostic evaluation of metallothionein expression in human colorectal neoplasms. Journal of Clinical Pathology 52: 876–879.
[40]
Ioachim E, Tsanou E, Briasoulis E, Batsis C, Karavasilis V, et al. (2003) Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12: 111–119.
[41]
Lee SS, Yang SF, Ho YC, Tsai CH, Chang YC (2008) The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncology 44: 180–186.
[42]
Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, et al. (2011) Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patient survival. Histopathology 59: 514–525.
[43]
Tuccari G, Giuffre G, Arena F, Barresi G (2000) Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histology and Histopathology 15: 1035–1041.
[44]
Yamasaki Y, Smith C, Weisz D, van Huizen I, Xuan J, et al. (2006) Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Urology 67: 530–535.
[45]
Surowiak P, Materna V, Gyorffy B, Matkowski R, Wojnar A, et al. (2006) Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. British Journal of Cancer 95: 339–346.
[46]
Fresno M, Wu WY, Rodriguez JM, Nadji M (1993) Localization of metallothionein in breast carcinomas - an immunohistochemical study. Virchows Archiv A, Pathological Anatomy and Histopathology 423: 215–219.
[47]
Oyama T, Takei H, Hikino T, Iino Y, Nakajima T (1996) Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 53: 112–117.
[48]
Goulding H, Jasani B, Pereira H, Reid A, Galea M, et al. (1995) Metallothionein expression in human breast-cancer. British Journal of Cancer 72: 968–972.
[49]
Jin RX, Chow VTK, Tan PH, Dheen ST, Duan W, et al. (2002) Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23: 81–86.
[50]
Hishikawa Y, Kohno H, Ueda S, Kimoto T, Dhar DK, et al. (2001) Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 61: 162–167.
[51]
Brown JJ, Xu H, Nishitani J, Mohammed H, Osborne R, et al. (2003) Potential biomarkers for head and neck squamous cell carcinoma. Laryngoscope 113: 393–400.
[52]
Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB (1997) Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. European Journal of Cancer 33: 1860–1864.
[53]
Dutsch-Wicherek M, Lazar A, Tomaszewska R, Kazmierczak W, Wicherek L (2013) Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment. Cell & Tissue Research.
[54]
Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, et al. (1999) Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: Correlation with p53 and proliferative cell nuclear antigen. Pathology Research and Practice 195: 809–814.
[55]
Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, et al. (2007) Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Research 27: 335–342.
[56]
Sochor J, Hynek D, Krejcova L, Fabrik I, Krizkova S, et al. (2012) Study of Metallothionein Role in Spinocellular Carcinoma Tissues of Head and Neck Tumours using Brdicka Reaction. International Journal of Electrochemical Science 7: 2136–2152.
[57]
McCluggage WG, Strand K, Abdulkadir A (2002) Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. International Journal of Gynecological Cancer 12: 62–65.
[58]
Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, et al. (2012) Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagnostic Pathology 7: 124.
[59]
Tan Y, Sinniah R, Bay BH, Singh G (1999) Metallothionein expression and nuclear size-in benign, borderline, and malignant serous ovarian tumours. Journal of Pathology 189: 60–65.
[60]
Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, et al. (2006) Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histology and Histopathology 21: 341–347.
[61]
Murphy D, McGown AT, Crowther D, Mander A, Fox BW (1991) Metallothionein levels in ovarian-tumors before and after chemotherapy. British Journal of Cancer 63: 711–714.
[62]
Germain I, Tetu B, Brisson J, Mondor M, Cherian MG (1996) Markers of chemoresistance in ovarian carcinomas: An immunohistochemical study of 86 cases. International Journal of Gynecological Pathology 15: 54–62.
[63]
Schmid KW, Greeff M, Hittmair A, Totsch M, Ofner D, et al. (1994) Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C-cells using monoclonal antimetallothionein antibody-E9. Endocrine Pathology 5: 114–122.
[64]
Krolicka A, Kobierzycki C, Pula B, Podhorska-Okolow M, Piotrowska A, et al. (2010) Comparison of Metallothionein (MT) and Ki-67 Antigen Expression in Benign and Malignant Thyroid Tumours. Anticancer Research 30: 4945–4949.
[65]
Nartey N, Cherian MG, Banerjee D (1987) Immunohistochemical localization of metallothionein in human thyroid-tumors. American Journal of Pathology 129: 177–182.
[66]
Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, et al. (2008) Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Laboratory Investigation 88: 474–481.
[67]
Wei H, Desouki MM, Lin S, Xiao D, Franklin RB, et al. (2008) Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Molecular Cancer 7.
[68]
Yamasaki M, Nomura T, Sato F, Mimata H (2007) Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncology Reports 18: 1145–1153.
[69]
Franklin R, Feng P, Milon B, Desouki M, Singh K, et al. (2005) hZIP 1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Molecular Cancer 4: 32.
[70]
Suzuki T, Yamanaka H, Tamura Y, Nakajima K, Kanatani K, et al. (1992) Metallothionein of prostatic tissues and fluids in rats and humans. Tohoku Journal of Experimental Medicine 166: 251–257.
[71]
Gumulec J, Masarik M, Krizkova S, Adam V, Hubalek J, et al. (2011) Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma. Current Medicinal Chemistry 18: 5041–5051.
[72]
Costello LC, Franklin RB (2012) Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity. Expert Review of Anticancer Therapy 12: 121–128.
[73]
Ebara M, Fukuda H, Hatano R, Saisho H, Nagato Y, et al. (2000) Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma. Journal of Hepatology 33: 415–422.
[74]
Huang GW, Yang LY (2002) Metallothionein expression in hepatocellular carcinoma. World Journal of Gastroenterology 8: 650–653.
[75]
Lu DD, Chen YC, Zhang XR, Cao XR, Jiang HY, et al. (2003) The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale Journal of Biology and Medicine 76: 55–62.
[76]
Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, et al. (2009) Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. International Journal of Oncology 35: 477–483.
[77]
Chan KYY, Lai PBS, Squire JA, Beheshti B, Wong NLY, et al. (2006) Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Modern Pathology 19: 1546–1554.
[78]
Nakayama A, Fukuda H, Ebara M, Hamasaki H, Nakajima K, et al. (2002) A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels. Biological & Pharmaceutical Bulletin 25: 426–431.
[79]
Kubo S, Fukuda H, Ebara M, Ikota N, Saisho H, et al. (2005) Evaluation of distribution patterns for copper and zinc in metallothionein and superoxide dismutase in chronic liver diseases and hepatocellular carcinoma using high-performance liquid chromatography (HPLC). Biological & Pharmaceutical Bulletin 28: 1137–1141.
[80]
Ebert MPA, Gunther T, Hoffmann J, Yu J, Miehlke S, et al. (2000) Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Research 60: 1995–2001.
[81]
Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, et al. (2006) p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. Journal of Surgical Oncology 93: 241–252.
[82]
Janssen AML, van Duijn W, Oostendorp-van de Ruit MM, Kruidenier L, Bosman CB, et al. (2000) Metallothionein in human gastrointestinal cancer. Journal of Pathology 192: 293–300.
[83]
Saika T, Tsushima T, Nasu Y, Akebi N, Noda M, et al. (1992) Histopathological study of metallothionein in bladder cancer and renal cell carcinoma. Nihon Hinyokika Gakkai Zasshi 83: 636–642.
[84]
Zhou XD, Sens DA, Sens MA, Namburi V, Singh RK, et al. (2006) Metallothionein-1 and-2 expression in cadmium- or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer. Toxicological Sciences 91: 467–475.
[85]
Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M, et al. (2001) Decreases of metallothionein and aminopeptidase N in renal cancer tissues. Journal of Biochemistry 129: 253–258.
[86]
Nguyen A, Jing Z, Mahoney PS, Davis R, Sikka SC, et al. (2000) In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Letters 160: 133–140.
[87]
Hoey JG, Garrett SH, Sens MA, Todd JH, Sens DA (1997) Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma. Toxicology Letters 92: 149–160.
[88]
Hellemans G, Soumillion A, Proost P, Van Damme J, Van Poppel H, et al. (1999) Metallothioneins in human kidneys and associated tumors. Nephron 83: 331–340.
[89]
Sugita K, Yamamoto O, Asahi M (2001) Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. American Journal of Dermatopathology 23: 29–35.
[90]
Zelger B, Hittmair A, Schir M, Ofner C, Ofner D, et al. (1993) Immunohistochemically demonstrated metallothionein expression in malignant-melanoma. Histopathology 23: 257–264.
[91]
Shukla VK, Aryya NC, Pitale A, Pandey M, Dixit VK, et al. (1998) Metallothionein expression in carcinoma of the gallbladder. Histopathology 33: 154–157.
[92]
Bruewer M, Schmid KW, Krieglstein CF, Senninger N, Schuermann G (2002) Metallothionein: Early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World Journal of Surgery 26: 726–731.
[93]
McCluggage WG, Maxwell P, Bharucha H (1998) Immunohistochemical detection of metallothionein and MIB1 in uterine cervical squamous lesions. International Journal of Gynecological Pathology 17: 29–35.
[94]
El Sharkarvy SL, Farrag ARH (2008) Mean nuclear area and metallothionein expression in ductal breast tumors: Correlation with estrogen receptor status. Applied Immunohistochemistry & Molecular Morphology 16: 108–112.
[95]
Tews DS, Nissen A, Kulgen C, Gaumann AKA (2000) Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. Journal of Neuro-Oncology 50: 227–237.
[96]
Bier B, Douglasjones A, Totsch M, Dockhorndworniczak B, Bocker W, et al. (1994) Immunohistochemical demonstration of metallothionein in normal human breast-tissue and benign and malignant breast-lesions. Breast Cancer Research and Treatment 30: 213–221.
[97]
Thirumoorthy N, Kumar KTM, Sundar AS, Panayappan L, Chatterjee M (2007) Metallothionein: An overview. World Journal of Gastroenterology 13: 993–996.
[98]
Eid H, Geczi L, Bodrogi I, Institoris E, Bak M (1998) Do metallothioneins affect the response to treatment in testis cancers? Journal of Cancer Research and Clinical Oncology 124: 31–36.
[99]
Meijer C, Timmer A, De Vries EGE, Groten JP, Knol A, et al. (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. International Journal of Cancer 85: 777–781.
[100]
Huang Y, De La Chapelle A, Pellegata NS (2003) Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. International Journal of Cancer 104: 735–744.
[101]
Dziegiel P, Jelen M, Muszczynska B, Maciejczyk A, Szulc A, et al. (2004) Role of metallothionein expression in non-small cell lung carcinomas. Roczniki Akademii Medycznej w Bialymstoku 49 Suppl 143–45.
[102]
Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, et al. (2004) Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. Journal of Gastroenterology 39: 1196–1201.
[103]
Johnson LA, Kanak MA, Kajdacsy-Balla A, Pestaner JP, Bagasra O (2010) Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands. Methods 52: 316–321.
[104]
Cortesi M, Fridman E, Volkov A, Shilstein SS, Chechik R, et al. (2008) Clinical assessment of the cancer diagnostic value of prostatic Zinc: A comprehensive needle-biopsy study. Prostate 68: 994–1006.
[105]
Bouzourene H, Chaubert P, Gebhard S, Boman FT, Coucke P (2002) Role of metallothioneins in irradiated human rectal carcinoma. Cancer 95: 1003–1008.
[106]
Li SY, Yu B, An P, Zuo FY, Cai HY (2005) Expression of metallothionein and FasL in colorectal cancer and its clinical significance. Zhonghua Wai Ke Za Zhi (Chinese Journal of Surgery) 43: 1118–1120.
[107]
Wulfing C, van Ahlen H, Eltze E, Piechota H, Hertle L, et al. (2007) Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. World Journal of Urology 25: 199–205.
[108]
Ioachim EE, Kitsiou E, Carassavoglou C, Stefanaki S, Agnantis NJ (2000) Immunohistochemical localization of metallothionein in endometrial lesions. Journal of Pathology 191: 269–273.
[109]
McCluggage WG, Maxwell P, Hamilton PW, Jasani B (1999) High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 34: 51–55.
[110]
Izawa JI, Moussa M, Cherian MG, Doig G, Chin JL (1998) Metallothionein expression in renal cancer. Urology 52: 767–772.
[111]
Zhang XH, Takenaka I (1998) Incidence of apoptosis and metallothionein expression in renal cell carcinoma. British Journal of Urology 81: 9–13.
[112]
Bay BH, Jin RX, Huang JX, Tan PH (2006) Metallothionein as a prognostic biomarker in breast cancer. Experimental Biology and Medicine 231: 1516–1521.
[113]
Dumanska M, Dziegiel P, Sopel M, Wojnar A, Zabel M (2004) Evaluation of apoptosis, proliferation intensity and metallothionein (MT) expression in comparison with selected clinicopathological variables in primary adenocarcinomas of the large intestine. Folia Morphologica (Poland) 63: 107–110.
[114]
DouglasJones AG, Navabi H, Morgan JM, Jasani B (1997) Immunoreactive p53 and metallothionein expression in duct carcinoma in situ of the breast - No correlation. Virchows Archiv 430: 373–379.
[115]
Gallicchio L, Flaws JA, Sexton M, Ioffe OB (2004) Cigarette smoking and metallothionein expression in invasive breast carcinomas. Toxicology Letters 152: 245–253.
[116]
Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, et al. (2010) Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochemica et Cytobiologica 48: 242–248.
[117]
Haerslev T, Jacobsen GK, Zedeler K (1995) The prognostic-significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 103: 279–285.
[118]
Zhang R, Zhang H, Wei H, Luo X (2000) Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. Journal of Environmental Pathology Toxicology and Oncology 19: 95–97.
[119]
Jin RX, Bay BH, Chow VTK, Tan PH (2001) Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Research and Treatment 66: 265–272.
[120]
Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, et al. (2000) Metallothionein immunoreactivity in head and neck carcinomas; Special reference to clinical behaviors and chemotherapy responses. Anticancer Research 20: 257–264.
[121]
Athanassiadou P, Bantis A, Gonidi M, Athanassiades P, Agelonidou E, et al. (2007) The expression of metallothioneins on imprint smears of prostate carcinoma: Correlation with clinicopathologic parameters and tumor proliferative capacity. Tumori 93: 189–194.
[122]
Moussa M, Kloth D, Peers G, Cherian MG, Frei JV, et al. (1997) Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. Clinical and Investigative Medicine-Medecine Clinique Et Experimentale 20: 371–380.
[123]
El Sharkawy SL, Abbas NF, Badawi MA, El Shaer MA (2006) Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. Journal of Clinical Pathology 59: 1171–1174.
[124]
Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemuller J, et al. (2001) Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. International Journal of Cancer 95: 121–127.
[125]
Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, et al. (2005) Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv 447: 626–633.
[126]
Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, et al. (2002) Expression of metallothionein in lung carcinoma: correlation with histological type and. Histopathology 40: 143–151.
[127]
Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, et al. (1999) Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. British Journal of Cancer 81: 712–720.
[128]
Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B (2007) Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. Journal of the European Academy of Dermatology and Venereology 21: 669–677.
[129]
Haerslev T, Jacobsen K, Nedergaard L, Zedeler K (1994) Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph-node metastases. Pathology Research and Practice 190: 675–681.
[130]
Schmid KW, Ellis IO, Gee JMW, Darke BM, Lees WE, et al. (1993) Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Archiv A, Pathological Anatomy and Histopathology 422: 153–159.
[131]
Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, et al. (2013) Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Experimental and Molecular Pathology 94: 301–308.
Ma HQ, Sun HH, Huang FX, Li J, Cao XL, et al. (2009) Expression of ERCC1, Bcl-2, MT and their Clinical Significance in Advanced Non-small-cell Lung Cancer Treated With Cisplatin-based Chemotherapy. Latin American Journal of Pharmacy 28: 827–834.
[134]
Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, et al. (2003) Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histology and Histopathology 18: 401–407.
[135]
Mitropoulos D, Kyroudi-Voulgari A, Theocharis S, Serafetinides E, Moraitis E, et al. (2005) Prognostic significance of metallothionein expression in renal cell carcinoma. World Journal of Surgical Oncology 3.
[136]
Aloia TA, Harpole DH, Reed CE, Allegra C, Moore MBH, et al. (2001) Tumor marker expression is predictive of survival in patients with esophageal cancer. Annals of Thoracic Surgery 72: 859–866.
[137]
Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, et al. (2001) Metallothionein expression in patients with small cell carcinoma of the lung - Correlation with other molecular markers and clinical outcome. Cancer 92: 836–842.
[138]
Ryvolova M, Adam V, Kizek R (2012) Analysis of metallothionein by capillary electrophoresis. Journal of Chromatography A 1226: 31–42.
